GTPase activating protein and VPS9 domains 1Genealiases: GAPEX5 · GAPex-5 · RAP6
Q-omics provides the consensus-scored GAPVD1 profile across patient tissues and cancer cell-line models. GAPVD1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GAPVD1 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, GAPVD1 RNA expression shows 21,100 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where GAPVD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPVD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPVD1 survival associations across molecular data types. GAPVD1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPVD1 RNA expression–survival associations across cancer types. High GAPVD1 expression shows unfavorable associations in ACC, HNSC, BLCA and UVM, but favorable associations in KIRC and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GAPVD1 RNA expression.
This table summarizes GAPVD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GAPVD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPVD1 shows lower tumor expression in THCA and higher tumor expression in LIHC, HNSC, BRCA, CHOL and BLCA. The THCA box plot shows higher GAPVD1 RNA expression in normal versus tumor tissue (log2 FC = −0.593, t-test p < 0.001).
This table shows molecular features associated with GAPVD1 in patient tissues and cancer cell lines. In patient samples, GAPVD1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GAPVD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
